Sanofi’s Big Bet on Integrated Patient Care, page-2

Nice find, MDSY.

Not so much the origin of Alan's quotes, as the fact that this is a global, industry-wide paradigm shift on how healthcare is strategized, formulated, developed and ultimately delivered, a shift that has been in process for some years. Again, for general background, read the SA article - Unilife and The Third Place in Healthcare. For more detailed analysis, read also the annual Ernst and Young Progressions Reports on Global Healthcare

The shift is very much technology enabled, from drug discovery through data mining and therapy delivery, and is rapidly gaining momentum. At a wider level it is also evidenced by participation of the likes of Apple, Google and Samsung in developing wearable medical devices to monitor personal health, and therapy requirements, on a 24/7 basis. Bluetooth all the way!

One of the key drivers is patient compliance. Non-compliance costs the healthcare industry, especially governments, billions of dollars a year. This then impacts the payers - insurers and the like.

So all the key industry stakeholders - pharma companies, governments, public and private healthcare providers, insuerers, medical device companies, and of course patients - you and me - have a vested interest, financial and personal, in making this work. We want the best therapies our money can buy.

It should come as no surprise that Unilife is in the box seat so far as injectable drug delivery platforms are concerned, or why the company is generating so much interest from payers and pharmas alike, for the "simple" reason that our platform technologies play a significant role in helping ensure therapy compliance with the end-user, the patient.

Unilife's products are the ultimate user-interface between the pharmaceutical companies and the patient. In this respect, Unilife is at once an industrial design company and an injectable drug delivery device company. Sound familiar?

The humble Unitract retractable safety syringe is not dead. It's genetic heritage lives on in all our products. Since our early beginnings when the Unitract was little more than a concept, the injectable drug delivery industry has made quantum leaps forward. As shareholders we are fortunate that the powers that be in Unilife saw the trend change ahead of time and were able to move fast enough to harness the future as it emerged. Research ''nimble" companies, and how important this is to ultimate success. I firmly believe had we not moved at the speed we have, and with the success we ahve, we would be dead, or at best an insignificant niche player watching an incredible opportunity pass us by.

Instead we find ourselves in an enviable, increasingly influential and dominant position, one that will soon pay handsomely for the patience of all concerned.

BTW On the subject of Bluetooth-enabled technology, don't think we're not working with the major players here. For our devices to talk to mobile phones, Unilife has to be talking with.....

Much more to come in this space. IMHO